the management

Søren Tulstrup, MSc
President & Chief Executive Officer

Søren Tulstrup has strong international experience within the pharmaceutical industry from working with Sandoz (now Novartis) and later with Merck & Co. Inc. Most recently he served as Vice President, Global Human Health at Merck & Co., Inc. In this capacity, he was a Member of the Diabetes & Obesity Franchise Global Operating Committee with overall responsibility for clinical development and commercial activities worldwide. Søren Tulstrup holds a BSc and an MSc in Economics and Business Administration from Copenhagen Business School and JL Kellogg Graduate School of Management, Northwestern University, Chicago.

Arthur A. Levin, PhD
VP & CDO and President, US Operations

Dr. Arthur Levin has over 15 years of experience in RNA-based research and development and 25 years of experience in the pharmaceutical industry. Before joining Santaris Pharma, Dr. Levin consulted for leading biotechnology and pharmaceutical companies, conducting research and development in RNA-based therapies such as mRNA, microRNA, and siRNA. Prior to consulting, Dr. Levin was Senior Vice President of Development at Isis Pharmaceuticals, where he was responsible for the drug development of Isis’ products across a range of therapeutic areas. He was instrumental in advancing more than a dozen antisense drugs from basic research to clinical development. Dr. Levin also held broad corporate responsibilities with investors and corporate partners. He joined Isis from Hoffmann-La Roche Inc. where he was Research Leader. Dr. Levin holds a PhD in Toxicology from the University of Rochester School of Medicine and Dentistry, New York and a BS in Biology from Muhlenberg College. He completed his post-doctoral work at the Chemical Industry Institute of Toxicology in Research Triangle, North Carolina. Dr. Levin is the author of more than 50 papers and book chapters.

Henrik Ørum MSc PhD
VP & Chief Scientific Officer

Henrik Ørum is a co-founder of Cureon A/S, which merged with Pantheco A/S to form Santaris Pharma. He was previously Director R&D and CSO at PNA Diagnostics A/S (formerly a subsidiary of Boehringer Mannheim and Hoffmann-La Roche) with responsibilities for the overall scientific and business strategy and intellectual property rights of the company.

Henrik Ørum is co-founder and previous board member of Exiqon A/S and co-founder of Cascade Aps. He holds a MSc in molecular biology from the Technical University of Copenhagen, a PhD in molecular biology from the Medical University of Copenhagen and post doc at the Copenhagen Royal School of Pharmacy. Henrik has extensive operational and strategic experience in all aspects of starting, developing, and managing biotech companies. He is the author and co-author of more than 40 scientific publications and books and has been issued out several patents. Henrik Ørum is often invited to speak at scientific and biotech conferences and symposia.

Michael R. Hodges, MD
VP & Chief Medical Officer

Michael R. Hodges, M.D., MBBS, BSc., MRCP has 20 years of biopharmaceutical development experience in both large pharmaceutical and biotechnology companies across a broad range of therapeutic areas, including infectious disease, oncology, respiratory and . dyslipidemia.  His career has included working on the development programs for the following commercial products: Vfend®, Diflucan®, Zithromax®, Tarceva® and Viagra®. Prior to joining Santaris Pharma A/S, Dr. Hodges, served as Chief Medical Officer for Altair Therapeutics Inc., a respiratory RNA therapeutic platform company. Dr. Hodges practiced internal medicine at several University of London hospitals and received board certification in internal medicine. Dr. Hodges received his undergraduate degree in Pharmacology from Kings College, and medical degree at the Westminster Medical School, University of London, UK. He currently serves on the Board of Directors of F2G, a biotechnology compound focused on developing anti-fungal drugs products.

Troels Koch, PhD
VP & Chief Technology Officer

Troels Koch is a co-founder of Cureon A/S, which merged with Pantheco A/S to form Santaris Pharma. He was previously Director of Chemistry & Operations at PNA Diagnostics A/S (a former subsidiary of Boehringer Mannheim and Hoffmann-La Roche).

Troels Koch is also a co-founder of Exiqon A/S.

Troels Koch has worked intensively with DNA, LNA, and PNA oligonucleotide technologies in the diagnostics and pharmaceutical industries. He has substantial experience in managing R&D activities, intellectual property rights and quality systems in biotech companies. He is the author and co-author of more than 60 scientific publications and books and 25 patents, and he is often invited to speak at scientific conferences and symposiums.

Troels Koch holds a MSc and a PhD in bioorganic chemistry obtained from the University of Copenhagen/University of Illinois.

Henrik Stage, MSc
VP & Chief Finance Officer

Henrik Stage is responsible for the Company's financial affairs as well as for business planning and financing, shareholder relations and financial negotiation with prospective corporate partners. Henrik Stage has a strong and diverse background in finance, operations, investor relations, business development and strategic planning, based on his experience from several senior executive positions at blue chip companies in Denmark, USA, Canada and Vietnam.

Soren Andersen, JD, MBA
VP & Chief Business Officer

Soren Andersen employs a broad array of international business experience within the pharmaceutical industry. Prior to joining Santaris Pharma A/S, Mr. Andersen was Vice President at Wyeth Discovery Research in Collegeville, Pennsylvania and in charge of heading the business functions within Wyeth Discovery Research. His management teams held responsibility for the global strategic planning, communications and operations within Discovery Research, as well as for the portfolio management and governance of 170+ research projects. Previously, he worked for Eli Lilly & Co Inc in the US and the UK, Lundbeck AS in Denmark and for GlaxoSmithKline Plc. in London. As a business entrepreneur, Mr. Andersen founded a start up fertility diagnostic device company and subsequently sold it. Mr. Andersen holds a Law Degree from University of Copenhagen and a MBA from Harvard Business School.

Bolette Wildt MSc
General Counsel & VP Human Resources

Bolette Wildt, General Counsel of Santaris Pharma, has extensive experience working as a corporate lawyer in the pharmaceutical industry, plus comprehensive knowledge within corporate law, employment law, contracts and licensing. She worked for Novo Nordisk for 15 years, as Assistant General Counsel and Head of Global People Mobility. Bolette Wildt holds a MSc in Law from the University of Copenhagen.